Weight Loss & Metabolic / side effects and safety / Last reviewed 2026-06-02

5-Amino-1MQ Side Effects: Safety Signals and Warnings

5-Amino-1MQ safety concerns are compound-specific. The main listed side effects are Limited safety data, No significant adverse effects reported in preclinical studies, and Potential for off-target methyltransferase inhibition at high doses (theoretical). The main warning signals are No human clinical trials completed, Technically a small molecule, not a peptide - regulatory classification differs, and Long-term safety profile unknown.

Read the full 5-Amino-1MQ guide Browse answer pages

Direct Answer

Evidence for 5-Amino-1MQ is too preliminary to support a research protocol with confidence. All published data is from mouse models in a single research group, with no human pharmacokinetic data and no independent replication. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or tesofensine have vastly stronger evidence bases as starting points.

Evidence grade
Level D
Research status
Preclinical
Category
Weight Loss & Metabolic
Best for
NNMT inhibition mechanistic research (preclinical only)

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Not FDA approved. Not scheduled. Available as a research chemical from specialty suppliers.

Evidence Snapshot

Evidence gradeLevel D
Research statusPreclinical
Best supported outcomesFat Mass Reduction (Level D) and NAD+ and Metabolic Enhancement (Level D)
Primary citation count2
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "5-Amino-1MQ Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/5-amino-1mq-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.